Introduction  {#s1}
=============

cAMP, the first second messenger discovered by Earl Sutherland in 1957, plays a crucial role in regulating a vast array of biological processes in all kingdoms of life by targeting PKA, Epac, cyclic nucleotide-gated ion channels, and Popdc proteins. cAMP is produced from ATP by adenylyl cyclases (ACs). Based on their structural and functional similarities, 9 transmembrane ACs (tmACs) in mammals are classified into four groups ([@bib40]). All tmACs share the common feature of containing two catalytic domains and an N-terminal domain. All tmACs except AC9 are activated by both the heterotrimeric G protein subunit Gsα and forskolin. Furthermore, the distinct AC isoforms are regulated differentially by myriad molecules, including Giα, Gβγ, calmodulin, PKA, PKC, protein associated with Myc (PAM), AKAP79/150, Snapin, and RGS2 ([@bib40]; [@bib58]). Surprisingly, almost all previous studies on ACs have focused on the regulation of their activities per se, and despite the pivotal role of ACs in cAMP signaling, next to nothing is known about the degradation of cell-surface ACs mediated by ubiquitination and/or other mechanisms that acutely and finely tune the signaling potential of cell-surface membrane proteins in response to environmental cues ([@bib42]; [@bib31]).

TRIP-Br1 belongs to a recently discovered protein family that includes TRIP-Br1 (SEI-1, SERTAD1), TRIP-Br2 (SEI-2, SERTAD2), TRIP-Br3 (SEI-3, HEPP, CDCA4), and RBT1 (SERTAD3) in mammals and TARA in *Drosophila* ([@bib23]; [@bib64]). The functions of TRIP-Br1 and other members of its family have not been fully characterized. Although earlier studies suggested that TRIP-Br1 in the nucleus acts as a transcriptional co-regulator of E2F-responsive genes, or forms an active quaternary complex with cyclin D/CDK4/INK4a to promote normal cell cycle progression ([@bib51]; [@bib20]), recent studies showed that endogenous TRIP-Br1 is predominantly localized in the cytoplasm and undergoes regulated nucleo-cytoplasmic transport ([@bib64]; [@bib18]; [@bib21]; [@bib19]; [@bib24]). Cytoplasmic TRIP-Br1 bound to 2 E3 ligases, XIAP and NEDD4-1, and prevented their ubiquitination and degradation ([@bib18]; [@bib21]), whereas it induced the ubiquitination and degradation of ASK1 (apoptosis signal-regulating kinase 1) and PKC-δ ([@bib19]; [@bib24]). However, physical interaction between TRIP-Br1 and ASK1/PKC-δ has not yet been observed ([@bib19]; [@bib24]). XIAP, NEDD4-1, and ASK1 are predominantly cytoplasmic, but PKC-δ is localized in both the cytoplasm and the nucleus.

Results {#s2}
=======

TRIP-Br1 binds to AC1 {#s2-1}
---------------------

Our preliminary data indicated that exogenous TRIP-Br1 may interact with AC1. Further study suggested that endogenous TRIP-Br1 and AC1 coprecipitated from HeLa cell extracts ([Figure 1a](#fig1){ref-type="fig"}), and a GST-TRIP-Br1 fusion protein---but not GST alone---pulled down HA-tagged AC1 from HEK293T cells ([Figure 1b](#fig1){ref-type="fig"}). In addition, AC1 colocalized with TRIP-Br1 in HeLa cells, even in a super-resolution microscopy analysis ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Next, we mapped the interaction sites in both TRIP-Br1 and AC1. TRIP-Br1 amino acids 50--82, which contain the SERTA domain, appeared to be required for binding AC1 ([Figure 1b](#fig1){ref-type="fig"}), whereas AC1 amino acids 236--612 (AC1-M), which include catalytic domain 1 (C1; aa 293--612), bound to TRIP-Br1 in pairwise pull-down assays ([Figure 1c--d](#fig1){ref-type="fig"}), indicating a direct binding of AC1-M with TRIP-Br1. Further mapping showed that catalytic domain 1b (C1b; aa 494--612) of AC1 is sufficient for binding TRIP-Br1 ([Figure 1c and e](#fig1){ref-type="fig"}).10.7554/eLife.28021.002Figure 1.TRIP-Br1 interacts with AC1.(**a**) Endogenous AC1 in HeLa cells was immunoprecipitated (IP) with anti-AC1 antibody or control IgG and immunoblotted with anti-AC1 (top) and anti-TRIP-Br1 antibodies (bottom). (**b**) GST-TRIP-Br1 truncation mutants (bottom) were used to pull down HA-AC1 (middle) expressed in HEK293T cells. The domains included in the GST-TRIP-Br1 truncation mutants are illustrated in the schematic of TRIP-Br1 (top). \*undegraded GST-TRIP-Br1 fragments. (**c**) Schematic of AC1. N, N-terminus; C1 and C2, catalytic domains 1 and 2, respectively; filled areas, transmembrane domains; M, cytosolic region between the 2 transmembrane domains. (**d**) Three purified FLAG-His-tagged AC1 fragments, AC1-N, AC1-M, and AC1-C2 (bottom), were used to pull down purified TRIP-Br1 (His-tagged at both N and C termini, top). CTRL, control: bovine serum albumin used instead of FLAG-His-tagged AC1 fragments. (**e**) GST-TRIP-Br1 was used to pull down GFP-tagged AC1 N-terminus and truncation fragments of C1 domain expressed in HEK293T cells. All experiments shown here are representative of 3--5 independent experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.28021.002](10.7554/eLife.28021.002)10.7554/eLife.28021.003Figure 1---figure supplement 1.Colocalization of AC1 with TRIP-Br1.(**a**) Confocal images of HeLa cells transfected with 3HA-AC1. The cells were immunostained with anti-HA and anti-TRIP-Br1 antibodies. (**b--c**) Confocal images of untransfected HeLa cells. Anti-AC1 antibody was delivered into live cells by Lipofectamine2000, and the signal of anti-AC antibody was amplified by Atto 488-conjugated biotin because endogenous AC1 was barely detectable by conventional immunostaining (**b**). (**c**) is a control without anti-AC1 primary antibody for **b**. (**d**) STORM (stochastic optical reconstruction microscopy) image of non-transfected HeLa cells immuno-stained with anti-AC1 and anti-TRIP-Br1 antibodies. Because the optical depth of the image is 200 nm, endogenous AC1 and TRIP-Br1 probably interacted directly in or near the plasmalemma. Scale bars: 20 µm in **a--c**, and 500 nm in **d**.**DOI:** [http://dx.doi.org/10.7554/eLife.28021.003](10.7554/eLife.28021.003)

TRIP-Br1 promotes AC1 degradation {#s2-2}
---------------------------------

To assess the functional impact of TRIP-Br1 binding to AC1, we first examined AC1 protein expression in the presence and absence of TRIP-Br1. Stable expression of TRIP-Br1-V5 markedly reduced the total and cell-surface protein levels of endogenous AC1 in HEK293T cells ([Figure 2a](#fig2){ref-type="fig"}), but exerted little effect on other membrane proteins such as endogenous transferrin receptor ([Figure 2a](#fig2){ref-type="fig"}) and exogenous TRPV4 and TRPP2 ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Agreeing with this observation, stable expression of TRIP-Br1-V5 also substantially reduced the protein level and forskolin-stimulated cAMP production of exogenous AC1 in HEK293T cells (Figure 6b--d). Conversely, knocking down TRIP-Br1 with two different shRNAs elevated AC1 protein expression in HeLa cells ([Figure 2b](#fig2){ref-type="fig"}). Furthermore, knocking out TRIP-Br1 in mice increased AC1 protein expression by 2--4 folds in heart tissue, adipocytes, and the brain ([Figure 2c](#fig2){ref-type="fig"}) without affecting AC1 mRNA levels ([Figure 2---figure supplement 1c](#fig2s1){ref-type="fig"}), which indicates that TRIP-Br1 regulates AC1 expression through a non-transcriptional function. Although TRIP-Br1 in the brain was too scarce to detect using our anti-TRIP-Br1 antibody, it greatly impacted AC1 protein expression ([Figure 2c](#fig2){ref-type="fig"}).10.7554/eLife.28021.004Figure 2.TRIP-Br1 promotes AC1 degradation.(**a**) Stable expression of TRIP-Br1-V5 markedly reduced total and cell-surface protein levels of endogenous AC1 in HEK293T cells. Cell-surface AC1 was biotinylated and isolated. Transferrin receptor: loading control. Quantification of the western blots is shown at the top: \*\*, different from the control cell (CTRL), p=0.0053; \*p=0.048; n = 3 independent experiments. (**b**) Knocking down TRIP-Br1 with two different shRNAs (shTRIP-Br1-1 and shTRIP-Br1-2) increased AC1 protein expression in HEK293T cells. Actin: loading control. (**c**) Knocking out TRIP-Br1 in mice elevated AC1 expression in heart tissue (n = 8, p=0.01), and adipocytes (n = 4, p=0.049), and the brain (n = 3, p=0.011). (**d**) Changes in the expression of endogenous AC1 with or without shTRIP-Br1-1 treatment were examined for 12 hr after CHX treatment in HEK293T cells (upper). The results are quantified in the lower panel; \*, different from control (CTRL), p=0.013 (6 h); \*\*p=0.004 (12 h); n = 3. (**e**) Effect of proteasomal and lysosomal inhibitors on endogenous AC1 in HEK293T cells. Baf, bafilomycin A1; CQ, chloroquine diphosphate. Quantification of the western blots is shown at the top: \*, different from the control (CTRL), p=0.029; n = 3 independent experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.28021.004](10.7554/eLife.28021.004)10.7554/eLife.28021.005Figure 2---figure supplement 1.Effect of TRIP-Br1 on the expression of other membrane proteins and AC1 mRNA levels.(**a--b**) Stable expression of TRIP-Br1-V5 did not affect the protein levels of HA-tagged TRPV4 (transient receptor potential vanilloid 4) (**a**) and TRPP2 (transient receptor potential polycystin 2) (**b**) transiently expressed in HEK293T cells. GAPDH, loading control; GFP, transfection efficiency control. (**c**) AC1 mRNA levels showed no change (compared to control) in the heart tissue of TRIP-Br1 knockout mice in a real-time PCR assay (WT n = 5, KO n = 4; p=0.853). The mRNA level of AC1 was normalized relative to that of GAPDH.**DOI:** [http://dx.doi.org/10.7554/eLife.28021.005](10.7554/eLife.28021.005)

To explore how TRIP-Br1 reduces AC1 protein expression, we added the protein-synthesis blocker cycloheximide (CHX) to HeLa cells. Knocking down TRIP-Br1 considerably slowed down the degradation of endogenous AC1 ([Figure 2d](#fig2){ref-type="fig"}). The degradation of endogenous AC1, seemed to be mainly through a proteasomal pathway, because proteasomal but not lysosomal inhibitors significantly elevated AC1 expression ([Figure 2e](#fig2){ref-type="fig"}).

TRIP-Br1 bridges the interaction of AC1 with XIAP E3 ligase {#s2-3}
-----------------------------------------------------------

How does TRIP-Br1 promote AC1 degradation? Because TRIP-Br1 reportedly binds to XIAP ([@bib18]), a RING E3 ligase, we tested whether TRIP-Br1 recruits XIAP to AC1 and thereby promotes AC1 ubiquitination and degradation. First, we verified the interaction between TRIP-Br1 and XIAP by using GST pull-down assays. GST-TRIP-Br1 fusion protein but not GST alone captured XIAP purified from *Escherichia coli*, which demonstrated a potential direct interaction between XIAP and TRIP-Br1 ([Figure 3a](#fig3){ref-type="fig"}). Furthermore, we mapped the XIAP binding site in TRIP-Br1 to the first 49 amino acids of TRIP-Br1 ([Figure 3a](#fig3){ref-type="fig"}). By contrast, purified FLAG-His-tagged AC1-N, AC1-M, and AC1-C2 ([Figure 1c](#fig1){ref-type="fig"}) did not coprecipitate with purified XIAP, which indicated a lack of direct interaction between XIAP and AC1 ([Figure 3b](#fig3){ref-type="fig"}). However, FLAG-His-tagged AC1-M coprecipitated with purified XIAP in the presence of TRIP-Br1 ([Figure 3b](#fig3){ref-type="fig"}), which strongly suggested that TRIP-Br1 bridges the interaction between XIAP and AC1. This is further supported by the co-immunoprecipitation experiments showing that endogenous AC1, TRIP-Br1, and XIAP form a macromolecular complex in HeLa cells ([Figure 3c](#fig3){ref-type="fig"}).10.7554/eLife.28021.006Figure 3.TRIP-Br1 bridges the interaction of AC1 with XIAP E3 ligase.(**a**) Full-length TRIP-Br1 fused with GST---but not GST-TRIP-Br1 truncation mutants or GST alone---captured His-XIAP purified from *E. coli*. (**b**) Three purified FLAG-His-tagged AC1 fragments, AC1-N, AC1-M, and AC1-C2, were used to pull down purified XIAP in the presence or absence of purified TRIP-Br1 (His-tagged at both N and C termini). (**c**) Endogenous AC1 in HeLa cells was IPed with anti-AC1 antibody or control IgG and immunoblotted with anti-AC1, anti-XIAP, and anti-TRIP-Br1 antibodies.**DOI:** [http://dx.doi.org/10.7554/eLife.28021.006](10.7554/eLife.28021.006)

We next tested whether XIAP binding results in AC1 ubiquitination and degradation and whether this process requires the presence of TRIP-Br1. Overexpression of wild-type XIAP, but not its H467A and F495A mutants that lack E3 ligase activity ([@bib63]; [@bib8]), markedly reduced the expression of endogenous AC1 and increased its ubiquitination in HeLa cells ([Figure 4a](#fig4){ref-type="fig"}), implying that XIAP E3 ligase directly or indirectly targets AC1. Moreover, overexpression of TRIP-Br1-FLAG lowered the expression of endogenous AC1 in HeLa cells as in HEK293T cells ([Figure 2](#fig2){ref-type="fig"}), and also elevated the ubiquitination of endogenous AC1 ([Figure 4a](#fig4){ref-type="fig"}); this suggested that TRIP-Br1 promotes the ubiquitination and degradation of AC1. Conversely, knockdown of XIAP or TRIP-Br1 with 2 or 3 different shRNAs produced the opposite effect of XIAP or TRIP-Br1 overexpression on endogenous AC1, respectively ([Figure 4b--c](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}, and [Figure 2b](#fig2){ref-type="fig"}). More importantly, the effect of XIAP on AC1 was almost abolished following extensive knockdown of endogenous TRIP-Br1 ([Figure 4b](#fig4){ref-type="fig"}), and vice versa ([Figure 4c](#fig4){ref-type="fig"}), and this suggested that XIAP and TRIP-Br1 collaboratively ubiquitinate and degrade AC1. Furthermore, in in vitro ubiquitination assays performed using only purified proteins, AC1 ubiquitination by XIAP required the presence of TRIP-Br1 ([Figure 5c](#fig5){ref-type="fig"}). Significantly, deleting the RING domain of XIAP in mice, in addition to increasing XIAP expression ([@bib48]), markedly increased AC1 protein expression in heart tissue, adipocytes, and the brain, which clearly demonstrated that the E3 ligase activity of XIAP modulates AC1 expression in vivo ([Figure 4d](#fig4){ref-type="fig"}). In addition, deleting the RING domain of XIAP abolished the effect of TRIP-Br1 knockout in the mouse brain ([Figure 4e](#fig4){ref-type="fig"}), further fortifying the notion that XIAP and TRIP-Br1 act in concert ([Figure 4b--c](#fig4){ref-type="fig"}). On the basis of all these results, we conclude that TRIP-Br1 acts as an adaptor for the ubiquitination and degradation of AC1 by XIAP E3 ligase.10.7554/eLife.28021.007Figure 4.XIAP binding results in AC1 ubiquitination and degradation in a TRIP-Br1 dependent manner.(**a--c**) Ubiquitinated and total endogenous AC1 were examined following overexpression of HA-XIAP or its 2 mutants (H467A and F495A) and TRIP-Br1-FLAG in control HeLa cells (**a**) and in HeLa cells in which we knocked down TRIP-Br1 (**b**) or XIAP (**c**). shTRIP-Br1-1 and shXIAP-1, small hairpin RNA; Ub, ubiquitin; GAPDH, loading control. Loading of immunoprecipitated AC1 (or other AC isoforms) was normalized (adjusted to equal amounts) to clearly reveal the differences in ubiquitination of AC1 (or other AC isoforms) in this and other figures. Total endogenous AC1 levels in panels **a--c**) are quantified in their respective top bar graphs: \*, different from control, p≤0.041; \*\*p=0.0019; \*\*\*p\<0.0001; n = 3 for all three panels. (**d**) Deleting the RING domain in XIAP in mice elevated AC1expression in heart tissue, adipocytes, and the brain. \*, different from control, p≤0.045, n = 4 for all 3 tissues. Connected dashes, XIAP; arrowhead, nonspecific band. (**e**) Deleting the RING domain in XIAP in mice eliminated TRIP-Br1's effect on AC1 in the brain. N.S., not different from TRIP-Br1, p=0.943, n = 4. In panels **d** and **e**, actin, loading control; transferrin receptor, membrane-protein negative control.**DOI:** [http://dx.doi.org/10.7554/eLife.28021.007](10.7554/eLife.28021.007)10.7554/eLife.28021.008Figure 4---figure supplement 1.Effect of two other XIAP shRNAs on AC1 protein expression.In addition to the XIAP shRNA sequence (shXIAP-1) used in [Figure 4c](#fig4){ref-type="fig"}, two other different XIAP shRNAs (shXIAP-2 and shXIAP-3) were used to knock down endogenous XIAP in HeLa cells to exclude off-target effects of XIAP shRNAs. Actin, loading control.**DOI:** [http://dx.doi.org/10.7554/eLife.28021.008](10.7554/eLife.28021.008)10.7554/eLife.28021.009Figure 4---figure supplement 2.cIAP1 and cIAP2 do not affect AC1 expression.(**a**) GST-TRIP-Br1 fusion protein or GST alone was used to pull down endogenous XIAP, cIAP1, and cIAP2 in Hela cells. (**b**) Overexpression of XIAP but not cIAP1 or cIAP2 degraded endogenous AC1 in Hela cells.**DOI:** [http://dx.doi.org/10.7554/eLife.28021.009](10.7554/eLife.28021.009)10.7554/eLife.28021.010Figure 5.Conserved residue K1047 is the XIAP ubiquitin-conjugation site in AC1.(**a**) Left panel: Effect of Lys-to-Arg mutations in HA-tagged AC1 (HA-AC1) on XIAP-induced AC1 degradation in HEK293T cells. Quantification of the western blots is shown at the top: \*, different from wild-type (WT) AC1 in the presence of XIAP, p=0.013, n = 3--6 independent experiments for various AC1 mutants. Right panel: relative cAMP production of WT and K1047R AC1 in the presence of XIAP. \*\*p=0.0038. (**b**) Effect of K1047R and K1049R mutations in HA-AC1 on XIAP-induced ubiquitination and degradation of HA-AC1 in HEK293T cells. (**c**) In vitro ubiquitination of AC1 and its K1047R and K1049R mutants. E1, ubiquitin-activating enzyme; Ub, ubiquitin. All experiments shown here are representative of 3 independent experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.28021.010](10.7554/eLife.28021.010)10.7554/eLife.28021.011Figure 5---figure supplement 1.XIAP induces K27-linked polyubiquitination of AC1.HEK293T cells were transfected with AC1 plus either XIAP-Myc or empty vectors (**a**, top and second panels). AC1 was immunoprecipitated from the two groups of cells and normalized to equal amounts (**a**, bottom panel) before subject to western blotting with K48, K27, or K63-linkage specific antibodies in panel **b**. AC1 polyubiquitinaton chains induced by XIAP appeared predominantly K27-linked. GAPDH, loading control; IgG, the heavy chains of anti-AC1 IgG used for IP are shown as a loading control. Shown here is representative of 3 independent experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.28021.011](10.7554/eLife.28021.011)10.7554/eLife.28021.012Figure 5---figure supplement 2.Endocytosis and recycling of HA-tagged wild-type and K1047R AC1 expressed in HeLa cells.(**a**) Upper panel: Effect of TRIP-Br1 and XIAP on the endocytosis of cell-surface wild-type and K1047R AC1. Lower panel: Summary data of 4 independent experiments similar to that shown in the upper panel. 'Endocytosed AC1' in the lower panel is the ratio of endocytosed AC to cell-surface AC in the upper panel. All data are normalized relative to data obtained for HA-AC1 alone. \*, different from wild-type AC1, p≤0.0232; \*\*p≤0.009. (**b**) Upper panel: Effect of TRIP-Br1 and XIAP on the recycling of endocytosed wild-type and K1047R AC1. Lower panel: Summary data of 3 independent experiments similar to that shown in the upper panel. 'AC remaining in the cytosol' is the ratio of remaining AC to 'input' (endocytosed AC) in the upper panel. All data are normalized relative to the data obtained for HA-AC1 alone.**DOI:** [http://dx.doi.org/10.7554/eLife.28021.012](10.7554/eLife.28021.012)

Among the IAP (inhibitor of apoptosis) family proteins, both cIAP1 and cIAP2 are closely related to XIAP and possess E3 ligase activity and a BIR2 domain. However, cIAP1 and cIAP2 did not or only weakly bound to TRIP-Br1([Figure 4---figure supplement 2a](#fig4s2){ref-type="fig"}), reflecting that their BIR2 domains lack the 3 amino acid residues critical for TRIB-Br1 binding ([@bib18]). Moreover, neither cIAP1 nor cIAP2 had any significant effect on AC1 protein expression ([Figure 4---figure supplement 2b](#fig4s2){ref-type="fig"}), suggesting that XIAP, among the three closely related IAP family proteins, specifically targets ACs.

The conserved residue K1047 is the XIAP-mediated ubiquitin-conjugation site in AC1 {#s2-4}
----------------------------------------------------------------------------------

Because TRRP-Br1 binds to the C1b domain of AC1, which shares high sequence similarity with the corresponding domains in other tmAC isoforms, we reasoned that TRIP-Br1 could potentially bind to all tmAC isoforms. Interestingly, our preliminary data suggested that TRIP-BR1 binds to multiple tmAC isoforms and TRIP-Br1 and XIAP appeared to promote the degradation of multiple AC isoforms (also see [Figures 6](#fig6){ref-type="fig"}--[7](#fig7){ref-type="fig"}). Thus, we reasoned that the sequences flanking the XIAP-mediated ubiquitination site(s) must be highly conserved in the distinct isoforms of AC. Based on sequence alignment ([Figure 6e](#fig6){ref-type="fig"}), 7 Lys residues flanked by highly conserved sequences in the cytoplasmic regions in multiple AC isoforms were identified and individually mutated to Arg in AC1. Notably, the K1047R mutation completely suppressed XIAP-induced AC1 degradation in HEK293T cells, whereas the other 6 mutations exerted negligible effects ([Figure 5a](#fig5){ref-type="fig"}). Moreover, the K1047R mutation almost eliminated XIAP-induced ubiquitination of AC1 ([Figure 5b](#fig5){ref-type="fig"}).10.7554/eLife.28021.013Figure 6.TRIP-Br1 binds to multiple AC isoforms and reduces their protein level and cAMP production.(**a**) GST-TRIP-Br1 captured ACs 2, 4, 5, 6, and 8. (**b**) Stable expression of TRIP-Br1-V5 reduced the protein expression of ACs 1, 2, 4, 5, 6, and 8 that were transiently expressed in HEK293T cells. (**c--d**) Quantification of protein levels of various AC isoforms in panel b and their forskolin-stimulated cAMP production. cAMP production is normalized relative to that of the control of mock cells. \*, different from control, p≤0.048; \*\*p≤0.009; \*\*\*p=0.001; n = 3--5. (**e**) Sequence alignment of the AC isoforms used in panel b to identify conserved Lys residues (boxed). Yellow highlight: identical residues; blue highlight: highly conserved.**DOI:** [http://dx.doi.org/10.7554/eLife.28021.013](10.7554/eLife.28021.013)10.7554/eLife.28021.014Figure 7.XIAP/TRIP-Br1 attenuates the expression of multiple AC isoforms.(**a**) Total endogenous AC2 and AC5/6 in HeLa cells were examined following overexpression of HA-XIAP and its H467A and F495A mutants and TRIP-Br1-FLAG (quantification in [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). (**b--c,**) Mutation to Arg of K1065 in HA-AC2 and K1247 in HA-AC5 abolished XIAP/TRIP-Br1-induced ubiquitination and degradation of HA-AC2 (**b**) and HA-AC5 (**c**), respectively, in HEK293T cells. The experiments shown here are representative of 3 independent experiments. (**d--e**) Knocking out TRIP-Br1 or the RING domain of XIAP in mice increased the expression of AC2 and AC5/6 in heart tissue. Transferrin receptor or Na/K ATPase: membrane-protein negative control; actin: loading control. \*, different for wild-type (WT), p≤0.036, n = 3; \*\*p≤0.006, n = 8. (**f**), Net cAMP production in response to IBMX (ΔIBMX, 100 μM) or forskolin (ΔFSK, 10 μM) in heart tissues of wild-type (WT), TRIP-Br1 knockout, and XIAP ΔRING mice. ΔIBMX and ΔFSK are the differences between IBMX-stimulated and control cAMP production, and between forskolin/IBMX- and IBMX-stimulated cAMP production, respectively (inset). \*, different from WT, p≤0.04; \*\*p≤0.006; \*\*\*p≤0.001, n = 8 wk-old females for all three groups. (**g**) Basal heart rates of wild-type (WT), TRIP-Br1 knockout, and XIAP ΔRING mice. \*\*, different from WT, p=0.0049; \*, p=0.032; 8-wk-old male and female littermates of WT (n = 5) and TRI-BR1 knockout mice (n = 6) or 4-wk-old male littermates of WT (n = 5) and XIAP ΔRING mice (n = 6) were used for experiments. The mice were anesthetized with Avertin. The difference in the basal heart rates of 4-wk-old and 8-wk-old WT mice has been reported before ([@bib33]).**DOI:** [http://dx.doi.org/10.7554/eLife.28021.014](10.7554/eLife.28021.014)10.7554/eLife.28021.015Figure 7---figure supplement 1.TRIP-Br1 bridges the interaction of AC2 and AC5/6 with XIAP E3 ligase.(**a**) Summary data of total endogenous AC2 and AC5/6 in [Figure 7a](#fig7){ref-type="fig"}. \*, different from control, p≤0.019; \*\*p≤0.008; **\*\*\***p\<0.0001; n = 3. (**b--c**) Total endogenous AC2 and AC5/6 in HeLa cells were examined following the overexpression of either HA-XIAP without and with TRIP-Br1 knockdown (**b**), or TRIP-Br1-FLAG without and with XIAP knockdown (**c**). shRNA, small hairpin RNA, and shTRIP-Br1-1 and shXIAP-1 were used here; GAPDH, loading control. Lower panels in **b** and **c**, summary data of their respective upper panels; \*p≤0.043; n = 3.**DOI:** [http://dx.doi.org/10.7554/eLife.28021.015](10.7554/eLife.28021.015)10.7554/eLife.28021.016Figure 7---figure supplement 2.Knocking out TRIP-Br1 in mice increased AC2 expression in the brain.Na/K ATPase: membrane-protein negative control; actin: loading control. Quantification of the western blots is shown at the right: \*, different from wild-type (WT), p=0.0138, n = 3 pairs of female littermates.**DOI:** [http://dx.doi.org/10.7554/eLife.28021.016](10.7554/eLife.28021.016)10.7554/eLife.28021.017Figure 7---figure supplement 3.Change in the heart rate of TRIP-Br-1 knockout mice under deep anesthesia.Heart rates of wild-type (WT) and TRIP-Br1 knockout (KO) mice under basal and isoproterenol-stimulated (iso) conditions; \*\*, different from WT, p=0.002; \*p=0.014; n = 12 (WT, basal); 15 (KO, basal); 7 (WT, iso); 7 (KO, iso). Instead of Avertin, the mice in these experiments were anesthetized with ketamine and xylazine, which induce deep anesthesia.**DOI:** [http://dx.doi.org/10.7554/eLife.28021.017](10.7554/eLife.28021.017)10.7554/eLife.28021.018Figure 7---figure supplement 4.Knocking out TRIP-Br1 induces the phosphorylation of CREB in the hippocampus and mood disorder (especially despair-like behavior) in mice.(**a**) Immunostaining of phosphorylated CREB (pCREB, red) in the hippocampus, with NeuN (green, neuronal marker) and DAPI (purple). (**b**) Quantitation of pCREB immunoreactivity relative to NeuN, \*, different from WT, p=0.024, n = 3 10 wk-old male mice for both WT and KO (TRIP-Br1 knockout). (**c**) Body weight of the mice. (**d**) Muscle strength in wire hanging test. (**e--i**) Mood disorders, especially despair-like behavior, in several tests: (**e**) immobility time in the forced swimming test; (**f**) Nesting score in 24 (left) and 48 (right) h; (**g**) time in open arms in an elevated plus maze; (**h**) latency to enter a light box (left) and time in the light box (right) in the light-dark transition test; (**i**) number of marble buried in the marble burying test. 9 (±1)-wk-old male and female mice used in the experiments in panels **c--I**, and ++, +/−, and −/− denote: wild-type (n = 9), heterozygous (n = 8), homozygous (n = 11) TRIP-Br1 knockout mice, respectively. Different from +/+: \*p≤0.039; \*\*p=0.007; \*\*\*\*p≤0.0005.**DOI:** [http://dx.doi.org/10.7554/eLife.28021.018](10.7554/eLife.28021.018)

To verify that XIAP catalyzes the ubiquitination of AC1 directly instead of through another E3 ligase, we assembled an in vitro ubiquitination system that contained the E1 ubiquitin-activating enzyme (Uba1), the E2 ubiquitin-conjugating enzyme (UbcH5b), ATP, ubiquitin, and the protein substrate (AC1 or its K1047R and K1049R mutants). The addition of the E3 ubiquitin ligase XIAP led to the ubiquitination of AC1 and its K1049R mutant but not its K1047R mutant, but this ubiquitination occurred only in the presence of TRIP-Br1 ([Figure 5c](#fig5){ref-type="fig"}); these results clearly demonstrated that XIAP directly ubiquitinates AC1 and conjugates ubiquitins at the K1047 residue in a TRIP-Br1-dependent manner.

The pattern of XIAP-induced ubiquitination of AC1 appeared to be polyubiquitination ([Figure 5](#fig5){ref-type="fig"}), and an analysis of the linkage type of the polyubiquitination suggested that it is predominantly K27-linked ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). K27-linked polyubiquitination has been implicated in proteasomal or lysosomal degradation of proteins ([@bib2]; [@bib62]; [@bib60]; [@bib43]; [@bib2]).

XIAP/TRIP-Br1-mediated ubiquitination accelerates AC1 endocytosis {#s2-5}
-----------------------------------------------------------------

TRIP-Br1 reduced the surface expression of AC1 and accelerated its degradation ([Figure 2a and d](#fig2){ref-type="fig"}); therefore, we tested whether TRIP-Br1-induced ubiquitination increases the endocytosis of cell-surface AC1 or hinders the recycling of AC1 from intracellular pools. We examined the effect of TRIP-Br1 and XIAP on the endocytosis and recycling rates of exogenous wild-type and K1047R AC1 in HeLa cells. Expression of both TRIP-Br1 and XIAP robustly increased the endocytic rate of cell-surface AC1 but exerted no effect on the recycling of intracellular AC1 ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}); more importantly, the K1047R mutation of AC1, which eliminates AC1 ubiquitination induced by TRIP-Br1/XIAP ([Figure 5b--c](#fig5){ref-type="fig"}), almost abolished the endocytosis of cell-surface AC1 in the absence and presence of TRIP-Br1 and XIAP ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). These results clearly demonstrate that TRIP-Br1/XIAP-induced ubiquitination of cell-surface AC1 accelerates its endocytosis and thereby increases its degradation.

XIAP and TRIP-Br1 control the expression of multiple AC isoforms {#s2-6}
----------------------------------------------------------------

Because TRIP-Br1 bound to the C1b domain in AC1, which is highly conserved among distinct AC isoforms, we hypothesized that TRIP-Br1 also binds to other AC isoforms. Our results showed that GST-TRIP-Br1 pulled down all five other AC isoforms tested: AC2, AC4, AC5, AC6, and AC8 ([Figure 6](#fig6){ref-type="fig"}). More importantly, the protein levels of these exogenous AC isoforms were also substantially diminished following TRIP-Br1 expression in HEK293T cells, as shown by the results of both western blotting and cAMP assays ([Figure 6b--d](#fig6){ref-type="fig"}).

Among these 5 AC isoforms, AC2 and AC5/6 were chosen for further examination of XIAP's involvement in their degradation, because AC1 ([Figures 1](#fig1){ref-type="fig"}--[6](#fig6){ref-type="fig"}), AC2, and AC5/6 represent 3 distinct classes of AC isoforms ([@bib40]). Because of their high homology, AC5 and AC6 cannot be differentiated using currently available antibodies. As in the case of AC1 ([Figure 4a](#fig4){ref-type="fig"}), expression of XIAP but not its H467A and F495A mutants and expression of TRIP-Br1-FLAG reduced the protein expression of endogenous AC2 and AC5/6 and increased the ubiquitination of enxogenous AC2 and AC5 ([Figure 7a--c](#fig7){ref-type="fig"}, and [Figure 7---figure supplement 1a](#fig7s1){ref-type="fig"}); this supports the conclusion that AC2 and AC5/6, like AC1, are substrates of the TRIP-Br1/XIAP E3 ligase complex. Conversely, knockdown of XIAP or TRIP-Br1 produced the opposite effect of XIAP or TRIP-Br1 overexpression on AC2 and AC5/6 ([Figure 7---figure supplement 1b--c](#fig7s1){ref-type="fig"}). Moreover, the effect of XIAP on AC2 and AC5/6 was almost abolished following extensive knockdown of endogenous TRIP-Br1, and vice versa ([Figure 7---figure supplement 1b--c](#fig7s1){ref-type="fig"}). These results indicated that XIAP and TRIP-Br1 also collaboratively ubiquitinate and degrade AC2 and AC5/6.

We also determined that when K1065 in AC2 and K1247 in AC5, which are both aligned with K1047 in AC1, were mutated to Arg, XIPA/TRIP-Br1-induced ubiquitination and degradation of AC2 and AC5 were eliminated ([Figure 7b--c](#fig7){ref-type="fig"}); this further bolstered the notion that XIAP/TRIP-Br1-mediated ubiquitination is a common mechanism for degrading multiple AC isoforms.

In agreement with the aforementioned results, knockout of TRIP-Br1 or deletion of the RING domain of XIAP (XIAP ΔRING) significantly increased expression of AC2 and AC5/6 in heart tissue and the brain in mice ([Figure 7d--e](#fig7){ref-type="fig"} and [Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}). Collectively, our data suggest that TRIP-Br1 acts as an adaptor for the ubiquitination and degradation of AC1, AC2, and AC5/6---and probably also other AC isoforms---by XIAP E3 ligase (Figure 9).

Functional changes of ACs in TRIP-Br1 knockout and XIAP ΔRING mice {#s2-7}
------------------------------------------------------------------

The increased protein expression of multiple AC isoforms, including major cardiac isoform AC5/6 ([@bib46]), in the heart tissue of TRIP-Br1 knockout and XIAP ΔRING mice ([Figure 7d--e](#fig7){ref-type="fig"}) promoted us to examine functional changes of ACs in these two mouse strains. The basal or forskolin-stimulated cAMP production of the heart tissue of the two mouse strains was significantly higher than that of wild-type mice ([Figure 7f](#fig7){ref-type="fig"}); these increases were independent of phosphodiesterases (PDEs) because PDE activities were blocked by the presence of the non-selective PDE inhibitor IBMX in the cAMP assay ([Figure 7f](#fig7){ref-type="fig"}). Consistent with the functional increase of cardiac ACs, the heart rates, which is regulated by AC (particularly AC5/6)-cAMP-PKA signaling ([@bib46]), were increased by \~8--17% under basal conditions in these two mouse strains, relative to that in wild-type mice ([Figure 7g](#fig7){ref-type="fig"}). This difference seemed to be greater when the mice were under deeper anesthesia (\~29% basal, and \~61% isoproterenol-stimulated; [Figure 7---figure supplement 3](#fig7s3){ref-type="fig"}), and the underlying mechanism is unclear at this time.

Alternatively, we assessed functional changes of ACs in the brain in TRIP-Br1 knockout mice because of increased protein expression of AC1 ([Figure 2c](#fig2){ref-type="fig"}) and AC 2 ([Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}), two major brain AC isoforms ([@bib46]), and possibly other AC isoforms ([Figures 6](#fig6){ref-type="fig"}--[7](#fig7){ref-type="fig"}). A modest yet significant increase in CREB (cAMP response element-binding protein) phosphorylation, a classical downstream effect of AC-cAMP-PKA signaling, was observed in the hippocampus in TRIP-Br1 knockout mice ([Figure 7---figure supplement 4a--b](#fig7s4){ref-type="fig"}). We further tested the functional impact of CREB phosphorylation in the hippocampus by evaluating the mood, especially despair-like behavior, of the mice because CREB phosphorylation in certain brain regions including the hippocampus is associated with depressive and anxiety-like behaviors ([@bib4]). Significantly, TRIP-Br1 knockout mice showed markedly decreased immobility time in the forced swimming test, very poor scores in the nesting test (especially in the first 24 hr), increased time in the open arms in an elevated plus maze, and moderately elongated stay in the light box in the light-dark transition test ([Figure 7---figure supplement 4e--h](#fig7s4){ref-type="fig"}), although they displayed apparently normal physical strengths as indicated by normal body weights and performance in the wire hanging test ([Figure 7---figure supplement 4c--d](#fig7s4){ref-type="fig"}); all these results suggest mood disorders, especially despair-like behaviors. The TRIP-Br1 knockout mice were also tested in the marble burying test but showed normal behavior ([Figure 7---figure supplement 4i](#fig7s4){ref-type="fig"}).

In sum, the increase in AC protein expression resulted in consistent changes in the heart and brain functions in TRIP-Br1 knockout and XIAP ΔRING mice.

Negative-feedback regulation of AC1 by XIAP/TRIP-Br1 {#s2-8}
----------------------------------------------------

What is the physiological significance of XIAP/TRIP-Br1 mediated downregulation of ACs? Because AC-cAMP-PKA signaling pathway is known to stabilize XIAP through CREB or PI3K signaling ([@bib5]; [@bib9]; [@bib13]; [@bib32]), we hypothesized that an increase in AC and PKA activities upregulates XIAP protein expression and subsequently downregulates AC protein expression in a negative-feedback manner. We tested this hypothesis in mouse primary cells, specifically in macrophages, because they reportedly upregulated XIAP upon forskolin stimulation ([@bib32]) and are relatively easy to culture. 6 hr treatment of either isoproterenol or forskolin, two commonly used AC/cAMP agonists, increased XIAP protein expression, and, more importantly, markedly decreased AC1 protein expression in the macrophages of wild-type mice in a PKA-inhibitor-sensitive manner ([Figure 8a--b](#fig8){ref-type="fig"}). By contrast, the two agonists had no impact on TRIP-Br1 protein expression ([Figure 8a--b](#fig8){ref-type="fig"}). Significantly, ablation of TRIP-Br1 gene nullified the regulatory effects of the cAMP agonists on AC1 protein expression while had little impact on the agonists' effects on XIAP protein expression ([Figure 8c--d](#fig8){ref-type="fig"}). These observations indicated that cAMP-PKA signaling regulates AC1 expression through increasing XIAP in a negative-feedback manner and TRIP-Br1 is an indispensable part of this negative-feedback loop.10.7554/eLife.28021.019Figure 8.cAMP agonists promote XIAP upregulation and AC1 degradation in a PKA-dependent manner in the macrophages of wild-type but not TRIP-Br1 knockout mice.Changes in AC1, XIAP, and TRIP-Br1 expression with or without 6 hr forskolin (FSK, 10 μM, in the presence of 100 μM IBMX) or isoproterenol (ISO,10 μM) treatment in the microphages of wild-type (**a--b**) and TRIP-Br1 knockout (**c--d**) mice. H89 (10 μM), PKA inhibitor; β-actin, loading control. (**b** and **d**), Summary data of panels **a** and **b**, respectively, relative to β-actin. Different from control (CTRL), \*p≤0.0427; \*\*p≤0.0076, n = 3.**DOI:** [http://dx.doi.org/10.7554/eLife.28021.019](10.7554/eLife.28021.019)

Discussion {#s3}
==========

A general mechanism for ubiquitinating and degrading tmACs {#s3-1}
----------------------------------------------------------

Ubiquitination regulates the trafficking and degradation of several molecules in the G-protein-coupled receptor (GPCR) signaling pathway, such as GPCRs, Gαs, beta-arrestin1/2, GRK2, RGS7, PDE4D5, and PKA ([@bib59]; [@bib61]; [@bib28]; [@bib37]), which are either critical upstream modulators or downstream targets of cellular AC functions. Thus, it is surprising that almost nothing is known about how the degradation of AC per se is regulated through ubiquitination or other mechanisms. Two early studies suggested that AC degradation was mediated by the lysosome ([@bib44]) or the proteasome ([@bib54]), but the mechanisms were unclear; and, PAM, an E3 ubiquitin ligase, was reported to bind and inhibit AC5 and AC6, although its inhibitory effect on the ACs was apparently independent of the ubiquitin-ligase activity ([@bib41]). Thus, our findings provide the first mechanism of AC degradation, and, notably, this mechanism appears to apply to 6 out of 9, if not all, tmAC isoforms ([Figure 9](#fig9){ref-type="fig"}).10.7554/eLife.28021.020Figure 9.A model depicting a general negative-feedback mechanism of ubiquitination and degradation of multiple AC isoforms.The SERTA domain of TRIP-Br1 binds to the C1b catalytic domain of AC1 or other AC isoforms and subsequently recruits XIAP, which, together with the E2 enzyme UbcH5b (or UbcH5a or UbcH5c) ([@bib36]; [@bib30]), ubiquitinates K1047 in AC1 or an equivalent Lys residue in other AC isoforms. The N-terminus of TRIP-Br1 interacts with XIAP, probably with its BIR2 domain ([@bib18]), and the Ring domain of XIAP interacts with UbcH5b ([@bib36]; [@bib30]). The ubiquitination of ACs leads to their endocytosis and degradation. Sustained AC activation and cAMP production under catecholamine stress increase XIAP protein expression through PKA, and elevated XIAP protein expression subsequently dstabilizes ACs and eventually lows cAMP production/signaling. Red arrow, stimulatory effect; black dash: inhibitory effect.**DOI:** [http://dx.doi.org/10.7554/eLife.28021.020](10.7554/eLife.28021.020)

Distinct AC isoforms share high structural homology, particularly in their 2 catalytic domains, and thus it is not unexpected that AC isoforms are controlled by common regulatory mechanisms. For instance, Gsα and P-site analogs bind to all tmACs and modulate their activity, and forskolin binds and stimulates all tmACs except AC9. Our study adds another common regulatory mechanism to this list. As in the case of other regulatory proteins and chemicals that control tmACs, the highly conserved C1b and C2 domains of tmAC contain the binding site of TRIP-Br1 and the ubiquitination site of XIAP, respectively ([Figure 9](#fig9){ref-type="fig"}).

TRIP-Br1 as an adaptor of E3 ligase {#s3-2}
-----------------------------------

TRIP-Br1 and other members of its family contain an N-terminal putative cyclin-A-binding domain, a novel highly conserved SERTA ([Se]{.ul}i-I, [R]{.ul}BT1, and [TA]{.ul}RA) domain of unclear function, a binding motif for PHD zinc finger- and/or bromodomain-containing proteins, and an acidic C-terminal domain ([@bib23]; [@bib20]), and these multiple protein-interaction domains in TRIP-Br1 enable it to act as an adaptor/scaffold protein and tethers different signaling components ([@bib20]; [@bib49]). Moreover, TRIP-Br1 appears to modulate their activity and expression of some of its interacting proteins ([@bib51]; [@bib19]; [@bib24]); however, whether this function of TRIP-Br1 needs a third protein is unclear. This study has shown that TRIP-Br1 acts as an adaptor by tethering ACs on its SERTA domain and XIAP E3 ligase on the N-terminal domain (which includes a putative cyclin-A-binding domain). The SERTA domain has been suggested to be involved in CDK4 binding and possibly homo-/hetero-dimerization ([@bib20]); by contrast, the function of the N-terminal putative cyclin-A-binding domain is largely unknown ([@bib20]). Our study has revealed previously unrecognized functions of these domains.

The adaptor proteins of E3 ubiquitin ligases not only facilitate specific interactions between E3 ubiquitin ligases and their substrates: they also alter the subcellular localization, activity, and stability of the corresponding ubiquitin ligases ([@bib25]). For example, the transcriptional regulator Smad7 binds to Smurf1/2 (2 Nedd4-family E3 ligases), and the nucleus-to-cytoplasm translocation of the Smad7-Smurf1/2 complex is triggered by TGF-β receptor activation ([@bib25]; [@bib6]). Smad7 not only acts as an adaptor for mediating the ubiquitination of TGF-β receptors by Smurf1/2, but also increases the activity of Smurf1/2 in several ways, including by blocking the auto-ubiquitination and degradation of Smurf1/2 ([@bib25]; [@bib6]). This is reminiscent of TRIP-Br1: like Smad7, TRIP-Br1 is a multi-functional protein, including regulating transcription and acting as an adaptor for XIAP E3 ligase. It is noted that cIAP1 and cIAP2, two IAP proteins highly homologous to XIAP, had virtually no functional interaction with TRIP-Br1/AC1 complex ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}), suggesting that XIAP specifically targets ACs.

An early study showed TRIP-Br1 knockout mice displayed no overt pathology, except for certain abnormalities in pancreatic islets, including a reduction in the number of islets and the area of beta-cells, impaired insulin secretion, and glucose intolerance; these presumably resulted from the loss of TRIP-Br1's regulatory function in cell cycle ([@bib11]). We observed a large increase in AC protein expression and cAMP production in the heart of TRIP-Br1 knockout mice, and this was accompanied by elevation in resting and stimulated heart rates ([Figures 2c](#fig2){ref-type="fig"} and [7d--g](#fig7){ref-type="fig"}, and [Figure 7---figure supplements 2](#fig7s2){ref-type="fig"}--[3](#fig7s3){ref-type="fig"}). Pathological effects of a marked increase in resting and stimulated heart rates might not be manifested in mice that are housed in a stress-free environment in the laboratory, at least not within the short period for which we observed the animals ([@bib46]). Similar results on the heart rate were obtained with mice that overexpressed AC5/AC6 ([@bib46]). Overexpression of ACs has also been previously shown to result in functional changes in the brain, such as alcohol dependency, learning and memory, and synaptic plasticity ([@bib46]; [@bib14]), and long-term studies are required to analyze these potential changes in TRIP-Br1 knockout mice. Interestingly, accompanying a robust increase in AC protein expression in the brain of ([Figure 2](#fig2){ref-type="fig"} and [Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}), we found a modest yet significant increase in CREB phosphorylation in the hippocampus and conspicuous mood disorders, especially despair-like behavior, in TRIP-Br1 knockout mice ([Figure 7---figure supplement 4](#fig7s4){ref-type="fig"}).

The activity and expression of TRIP-Br1 are altered in several physiological and pathological processes. TRIP-Br1 activity is modulated through its dephosphorylation by physically associated PP2A, but the kinase(s) that phosphorylates TRIP-Br1 remains unidentified ([@bib64]). Furthermore, TRIP-Br1 is induced in neurons following nerve growth factor deprivation and β-amyloid treatment and is required for neuronal cell death ([@bib3]), and TRIP-Br1 expression is also elevated in a cellular model of Parkinson's disease ([@bib45]) and in cancer cells ([@bib18]). Because cAMP promotes neuronal survival ([@bib26]) and suppresses Parkinson's disease ([@bib34]) and tumor formation ([@bib1]), future studies that enable segregation of multiple function of TRIP-BR1 must further investigate how and to what extent the regulatory function of TRIP-Br1 in AC-cAMP signaling, in addition to its transcriptional function, contributes to neuronal and other deficiencies.

XIAP E3 ligase and negative-feedback regulation of AC-cAMP-PKA signaling {#s3-3}
------------------------------------------------------------------------

The E3 ubiquitin-ligase function of XIAP is less well understood as compared to its inhibitory effect on caspases ([@bib12]). The identified substrates of XIAP E3 ligase include XIAP itself, XIAP-interacting proteins involved in apoptosis, and target proteins that perform other physiological functions, such as TAK1, MEKK2/3, and PTEN ([@bib12]; [@bib56]; [@bib53]). In addition, XIAP, independently of its E3 ligase, promotes the ubiquitination of C-RAF by recruiting CHIP ubiquitin ligase ([@bib10]). Although XIAP ΔRING mice, similar to XIAP knockout mice, are viable and apparently healthy, they showed increased expression of mutant XIAP ([@bib48]) ([Figure 4d](#fig4){ref-type="fig"}) and unexpected increased caspase activity ([@bib48]). These data indicate that XIAP E3 ligase activity targets XIAP itself and caspases. Our data demonstrated that XIAP ΔRING mice had increased AC expression and cAMP production ([Figures 4d](#fig4){ref-type="fig"} and [7e--f](#fig7){ref-type="fig"}), revealing that ACs are previously unidentified targets of XIAP E3 ligase activity in vivo.

XIAP is upregulated by AC-cAMP-PKA signaling through either PI3K signaling or CREB phosphorylation ([@bib5]; [@bib9]; [@bib13]; [@bib32]). Our data suggested that stimulating ACs through the AC agonists isoproterenol and forskolin increased XIAP protein expression and decreased AC1 protein expression in a PKA-dependent manner in mouse macrophages ([Figure 8](#fig8){ref-type="fig"}). Because XIAP destabilizes multiple AC isofroms, this negative-feedback regulation could apply to multiple AC isoforms and provide a mechanism to control the homeostasis of cAMP signaling ([Figure 9](#fig9){ref-type="fig"}). Various types of acute and chronic stressors trigger the systematic release of stress hormones including catecholamines that activates AC-cAMP-PKA signaling pathway, and acute and chronic catecholamine stress impairs cardiac myocytes ([@bib39]), wound healing ([@bib22]), and innate immune defense ([@bib47]). TRIP-Br1/XIAP-mediated negative-feedback regulation ([Figure 9](#fig9){ref-type="fig"}) could protect the body from such detrimental effects induced by catecholamine stress.

XIAP also interacts with TGF receptors and associated proteins ([@bib12]). Notably, all 3 TGF-β isoforms upregulate XIAP at the transcriptional level and thereby decrease PTEN expression ([@bib57], [@bib55]). Our findings raise the possibility that TGF-β downregulates ACs by enhancing XIAP expression. Intriguingly, treatment with TGF-β1 lowered AC activity in cardiomyocytes and prostate cancer cells, which suggests a possible reduction of AC protein expression ([@bib50]; [@bib35]). However, our preliminary study did not consistently observe TGF-dependent change of AC1 in mouse macrophages (not shown). In addition to TGF-β, XIAP is reportedly regulated by several other signaling pathways ([@bib17]; [@bib16]). Future work is needed to understand whether these signaling pathways are involved in the regulation of ACs, particularly in specific cell types.

In summary, ACs are critically important signaling molecules that are involved in diverse physiological processes such as cell growth and differentiation, learning and memory, olfaction, cardiac stress, and epithelial secretion. This study advances our understanding of the regulation of tmACs through protein-degradation mechanisms and identifies a previously unrecognized link between cAMP signaling and numerous signaling pathways that regulate either XIAP or TRIP-Br1. Particularly, we found that XIAP/TRIP-Br1-mediated degradation of tmACs forms part of a negative-feedback loop that controls the homeostasis of cAMP signaling. Our study can potentially open up new avenues of research and development for designing therapeutic approaches to control AC functions in health and disease.

Materials and methods {#s4}
=====================

Antibodies {#s4-1}
----------

Antibodies against the following proteins and tags were from commercial sources: TRIP-Br1, Enzo Life Science (RRID:[AB_2052741](https://scicrunch.org/resolver/AB_2052741)); XIAP, R and D Systems (RRID:[AB_2215008](https://scicrunch.org/resolver/AB_2215008)); AC1 (RRID:[AB_2223098](https://scicrunch.org/resolver/AB_2223098)), AC5/6 (RRID:[AB_2257941](https://scicrunch.org/resolver/AB_2257941)), ubiquitin (RRID:[AB_778730](https://scicrunch.org/resolver/AB_778730)), GAPDH (RRID:[AB_10847862](https://scicrunch.org/resolver/AB_10847862)), and β-actin (RRID:[AB_626632](https://scicrunch.org/resolver/AB_626632)), Santa Cruz Biotechnology; AC2, Novus Biologicals; V5 (RRID:[AB_2556564](https://scicrunch.org/resolver/AB_2556564)) and transferrin receptor (RRID: [AB_86623](https://scicrunch.org/resolver/AB_86623)), Life Technologies; HA (RRID:[AB_2314672](https://scicrunch.org/resolver/AB_2314672)), Covance; Ubiquitin (linkage-specific K27, K48, and K63), Abcam; Phospho-CREB, Cell Signaling Technology; NeuN, Millipore; and Na-K-ATPase (α subunit) (RRID:[AB_258029](https://scicrunch.org/resolver/AB_258029)) and FLAG M2 (antibody RRID:[AB_439685](https://scicrunch.org/resolver/AB_439685) and affinity gel RRID:[AB_10704031](https://scicrunch.org/resolver/AB_10704031)), Sigma-Aldrich.

cDNAs and plasmids {#s4-2}
------------------

The cDNAs of human TRIP-Br1 were amplified from Calu-3 cells by means of reverse transcription-PCR performed using SuperScript Reverse Transcriptase with oligo(dT)~12-18~ and Platinum Taq DNA polymerase (Invitrogen). The cDNAs of membrane ACs were kind gifts from other researchers: bovine AC1, Dr. Daniel R. Storm (University of Washington); rat AC2, Dr. Randall Reed (Johns Hopkins University); and rat AC4, rabbit AC5, rat AC6, and rat AC8, Dr. Zvi Vogel (Weizmann Institute of Science). The cDNAs of the membrane ACs were PCR-amplified and cloned into pCMV-3HA vectors. pRK5-Myc-XIAP was provided by Dr. Kenny Chung (Hong Kong University of Science and Technology), and pcDNA3-HA-XIAP and pcDNA3-HA-XIAP F495A were kind gifts from Dr. Philipp Jost (Technische Universität München). All XIAP cDNAs encoded human XIAP.

Cell culture and transfection {#s4-3}
-----------------------------

HEK293T (RRID: [CVCL_1926](https://scicrunch.org/resolver/CVCL_1926)) and HeLa (RRID: [CVCL_0030](https://scicrunch.org/resolver/CVCL_0030)) cells were obtained from ATCC. These cells were assumedly authenticated by ATCC and were not further authenticated in this study. All cell lines were routinely tested negative for mycoplasma contamination and maintained in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum and 100 U/mL penicillin/streptomycin (Life Technologies) in an atmosphere of 95% air-5% CO~2~ at 37°C. All transfections were performed using the Lipofectamine 2000 reagent kit (Invitrogen).

Mice {#s4-4}
----

TRIP-Br1(encoded by *Sertad1* gene) knockout mice (RRID: [MGI:4437096](https://scicrunch.org/resolver/MGI:4437096)) in a C57BL/6 genetic background were a kind gift from Dr. Manuel Serrano (Spanish National Cancer Research Center). XIAP ΔRING mice (RRID: [MGI:3809793](https://scicrunch.org/resolver/MGI:3809793)) was made by deleting the ring domain from the *Xiap* gene in a C57BL/6 genetic background as previously described ([@bib48]). Both mouse strains were genotyped using a PCR assay, according to previous reports ([@bib48]; [@bib11]). Unless indicated otherwise, wild-type mice were strain-, sex-, and age-matched with TRIP-Br1 knockout or XIAP ΔRING mice. All animal procedures were approved by the University Committee on Research Practices at the Hong Kong University of Science and Technology (the ethics protocol number 2014028).

Co-immunoprecipitation (co-IP) {#s4-5}
------------------------------

Co-IPs were performed using procedures described previously ([@bib52]), with minor modifications. After incubation with whole-cell extracts, Protein A Sepharose beads were washed 3 times with 500 µL of a 'Co-IP' lysis buffer ([@bib52]) plus 0.5% Triton X-100.

Pull-down assays {#s4-6}
----------------

GST or GST fusion proteins (5 μg) were incubated with glutathione-Sepharose beads (GE Healthcare) for 2 hr at 4°C in the Co-IP lysis buffer ([@bib52]), and then centrifuged at 500 × *g* for 1 min to pellet the beads; the beads were washed once with 500 μL of the Co-IP buffer. HEK293T cells transfected with various expression vectors for 24 hr were lysed with the Co-IP buffer (500 μL for cells in one 60 mm culture dish) and then centrifuged at 16,000 × *g* for 20 min. Next, the obtained supernatants were incubated (overnight, 4°C) with the Sepharose beads bound with GST/GST fusion proteins, after which the beads were washed five times (500 μL each time) with the Co-IP buffer plus 0.5% Triton X-100. The proteins bound on the beads were eluted using 60 μL of 1× SDS-PAGE loading buffer and analyzed by means of western blotting.

Pairwise pull-down assays {#s4-7}
-------------------------

For pairwise pull-down assays, all proteins were expressed in and purified from *E. coli* strain BL21 codon plus. The anti-FLAG M2 affinity gel (Sigma) was washed twice with a washing buffer (50 mM Tris-HCl, 150 mM NaCl, pH 7.4) and resuspended in the Co-IP buffer to prepare a 50% slurry, and then 5 μg of each protein and 40 μL of the gel suspension were mixed with the Co-IP buffer in a final volume of 500 μL and incubated for 2 hr at 4°C. Next, the gel was washed thrice with 500 μL of phosphate-buffered saline (PBS) containing 1% Triton X-100, and the bound proteins were eluted by incubating the resin with 100 μL of 0.1 M glycine-HCl, pH 3.5, for 5 min at room temperature. The resins were centrifuged for 30 s at 5000 × *g*, and then the supernatants were transferred to fresh test tubes containing 10 μL of 0.5 M Tris-HCl, 1.5 M NaCl, and pH 7.4; lastly, 6× SDS-PAGE loading buffer was added and the samples were subjected to western blotting analysis.

Preparation of mouse tissues for western blotting {#s4-8}
-------------------------------------------------

Tissues were dissected from mice, washed with PBS, and homogenized in RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton-100, 1 mM DTT, 1 mM PMSF, pH 7.4) supplemented with 1× protease-inhibitor cocktail; 500 μL of RIPA buffer was used for 30 mg of tissues. After sonication, tissue lysates were centrifuged at 16,000 × *g* for 20 min and the supernatants were used for western blotting.

Cycloheximide experiments {#s4-9}
-------------------------

HeLa cells with or without TRIP-Br1 shRNA treatment were treated with 200 μM CHX (Sigma) for various times. Subsequently, cells in both sets of experiments were lysed in radioimmunoprecipitation assay (RIPA) buffer (150 mM NaCl, 1.0% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 7.4) supplemented with a 1× protease-inhibitor cocktail (Roche). Cell lysates were analyzed by performing western blotting.

RNA interference {#s4-10}
----------------

Two different TRIP-Br1, and three different XIAP shRNAs ([@bib56]), and a scrambled and non-targeting control sequence were cloned into pSuper basic vectors. The sequences of the shRNAs are listed below:

shTRIP-Br1-1: 5′-gggcctgtttgaggatatt-3′;

shTRIP-Br1-2, 5'-GACACCTCTATGTATGACAAT-3';

shXIAP-1: 5′-GCCACGCAGTCTACAAATTCT-3′;

shXIAP-2: 5'-AGCTGTAGATAGATGGCAATA-3';

shXIAP-3:5'-GCACTCCAACTTCTAATCAAA-3';

sh-scrambled: 5′-ACGCATGCATGCTTGCTTT-3′.

Plasmids were transfected into HeLa cells by using Lipofectamine 2000 according to manufacturer instructions, and 24 hr after transfection, the cells were lysed with the Co-IP buffer supplemented with 1× protease-inhibitor cocktail (Roche) and 20 mM N-ethylmaleimide (NEM). Lysates were used for either western blotting or AC1 immunoprecipitation for ubiquitination assays.

Site-directed mutagenesis {#s4-11}
-------------------------

Point mutations in ACs were generated using a modified QuikChange reaction. KAPA HIFI polymerase PCR mixtures containing QuikChange primers and 20 ng of template were amplified for 16 cycles, and the PCR products were resolved using agarose gels and purified using a gel purification kit (Viogene). The purified DNA was digested with Dpn1 for 1 hr at 37°C, and this was followed by transformation into the bacterial strain DH5α. Clones were sequenced and plasmids were extracted using a miniprep kit (Viogene).

In vitro and in vivo ubiquitination assays {#s4-12}
------------------------------------------

His-AC1 was expressed in and purified from HEK293T cells. Briefly, 48 hr after transfection, cells were lysed using a Tris-NP-40 solubilization buffer: 20 mM Tris, 150 mM NaCl, 2 mM MgCl~2~, 10% glycerol, 5 mM imidazole, 0.1% NP-40, protease-inhibitor cocktail (Roche), 1 mM DTT, 1 mM PMSF, 5 mM ATP, pH 7.4. After sonication, intact cells and cell debris were removed by centrifuging the lysates at 16,000 × *g* for 20 min at 4°C. The supernatants were filtered through a porous membrane (pore diameter, 0.22 µm) and incubated with Ni-NTA beads (GE Healthcare) for 4 hr at 4°C. Subsequently, the beads were washed thrice (10 mL each time) with a washing buffer (same composition as the solubilization buffer, but containing 500 mM NaCl and 3 mM ATP) and eluted using an elution buffer (20 mM Tris, 150 mM NaCl, 2 mM MgCl~2~, 10% glycerol, 400 mM imidazole, 0.1% NP-40, pH 7.4). The eluted proteins were transferred to a ubiquitination reaction buffer (25 mM Tris-HCl, 5 mM MgCl~2~, 100 mM NaCl, 1 mM DTT, 2 mM ATP, pH 7.6) and concentrated to 1 mg/mL by using Amicon Ultra-15 Centrifugal Filter Units (Millipore; MWCO, 10 kD).

In vitro ubiquitination assays were performed following previously described procedures ([@bib38]; [@bib29]) and using an in vitro ubiquitination kit (ENZO Life). Briefly, purified His-AC1 was incubated with components of the putative ubiquitination machinery, including 100 ng of UBA1 (E1, ubiquitin-activating enzyme), 150 ng of UbcH5b (E2, ubiquitin-conjugating enzyme), 0.5 µg of XIAP, 2.5 µg of His-AC1, and 5 µg of ubiquitin, in a reaction buffer in a final volume 50 μL; the reaction buffer contained 25 mM Tris-HCl, 5 mM MgCl~2~, 100 mM NaCl, 1 mM DTT, and 2 mM ATP (pH 7.6). The mixture was incubated at 30°C for 4--6 hr and the reaction was terminated by adding 1× SDS-PAGE loading buffer. Ubiquitination of His-AC1 was analyzed by immunoblotting the proteins with anti-AC1 antibodies.

For in vivo ubiquitination assays performed for checking the ubiquitination status of endogenous AC1, HeLa cells were lysed (in the Co-IP buffer) 48 hr after transfection with various plasmids. The cell lysates were centrifuged at 16,000 × *g* at 4°C for 15 min, and 20% of the collected supernatants were immunoblotted to confirm the expression of each protein; the remaining supernatants were incubated with 1 μg of anti-AC1 antibody and 20 μL of Protein G Sepharose (GE Healthcare) overnight at 4°C. Immunoprecipitation experiments were performed in the Co-IP buffer supplemented with 1× protease-inhibitor cocktail (Roche) and 20 mM NEM. The recovered beads were washed three times with the Co-IP buffer supplemented with 0.5% Triton X-100 and heated in 1× SDS-PAGE sample loading buffer at 85°C for 20 min; the eluted proteins with immunoblotted with anti-AC1 or anti-ubiquitin antibodies (Santa Cruz Biotechnology).

Protein purification {#s4-13}
--------------------

Full-length TRIP-Br1 and its GST-fused fragments were expressed in and purified from *E. coli* strain BL21 codon plus. Briefly, GST expression vectors were transformed into *E. coli* and incubated overnight at 37°C in LB culture plates. Single colonies were picked and transferred into 20 mL of Terrific Broth (TB) and cultured overnight at 37°C. Subsequently, bacterial suspensions were transferred into 1 L of TB and cultured at 37°C for 3--4 hr (until OD600 reached 0.5--0.8), after which 0.5 mM IPTG was added and the cultures were incubated overnight at 16°C. Bacteria were collected through centrifugation (4000 × *g*, 5 min), washed once with 20 mL of PBS, and then pelleted again. Bacterial pellets were resuspended in 1× PBS and lysed using the French Pressure method. Cell debris and unbroken cells were removed through centrifugation at 12,000 × *g* for 20 min, and the collected supernatants were incubated (2 hr, 4°C) with glutathione-Sepharose beads (GE Healthcare). The beads were washed with PBS containing 1% Triton X-100 and eluted using reduced glutathione, and the eluted samples were dialyzed against 1× PBS for 24 hr.

His-UbcH5b (an E2 enzyme for XIAP \[[@bib36]; [@bib30]\]), His-Ub, His-TRIP-Br1, His-XIAP, His-AC1-N-FLAG, His-AC1-M-FLAG, and His-AC1-C2-FLAG were expressed in *E. coli* BL21 cells and purified using Ni-NTA beads (Qiagen). When purifying XIAP, 200 μM zinc sulfate was added to the culture medium and all solutions used for purification in order to maintain the activity of XIAP, because it is a zinc-coordinating protein ([@bib15]). Bacteria were cultured and collected using the same procedures as those described for the purification of GST proteins, and the collected bacteria were lysed in a lysis buffer (20 mM Tris-HCl, 500 mM NaCl, 10 mM imidazole, 10% glycerol, 1 mM PMSF, 1 mM DTT, pH 8.0). Next, cell debris and unbroken cells were removed through centrifugation (12,000 × *g*, 20 min), and the obtained supernatants were incubated with Ni-NTA beads (2 hr, 4°C). The beads were washed thrice (10 mL each time) with a washing buffer (20 mM Tris-HCl, 500 mM NaCl, 20 mM imidazole, 10% glycerol, 1 mM PMSF, 1 mM DTT, pH 8.0) and eluted using an elution buffer (20 mM Tris-HCl, 500 mM NaCl, 250 mM imidazole, 10% glycerol, 1 mM PMSF, 1 mM DTT, pH 8.0); the eluted samples were dialyzed (24 hr, 4°C) against a dialysis buffer (25 mM Tris-HCl, 150 mM NaCl, 10% glycerol, 1 mM DTT, pH 8.0). Protein concentrations were measured using a NanoDrop instrument and the concentration and quality of proteins were further verified using SDS-PAGE.

His-AC1-M-FLAG and His-AC1-C2-FLAG were mainly present in inclusion bodies. To purify these proteins, inclusion bodies were dissolved using 8 M urea, and the dissolved inclusion bodies were passed through a 25G needle 20 times. Proteins were refolded by sequentially diluting the urea to 4, 2, and 1 M with the lysis buffer. Insoluble components were removed through centrifugation (12,000 *g,* 20 min), and the collected supernatants were passed through 0.22 μm filters and then incubated with Ni-NTA beads for 2 hr at 4°C; the remaining procedures were the same as those described above.

Cell-surface biotinylation {#s4-14}
--------------------------

HEK293T cells stably expressing or not expressing TRIP-Br1 were seeded into 35 mm dishes 24 hr before labeling with biotin. Surface biotinylation was performed by using the cell-surface protein biotinylation and purification kit from Pierce with sulfo-NHS-SS-biotin, a thiol-cleavable amine-reactive biotinylation reagent. Briefly, cells were washed three times with PBS containing 1 mM MgCl~2~ and 0.1 mM CaCl~2~ (PBS-C/M) and then 1 mL of sulfo-NHS-SS-biotin (1 mg/mL in ice-cold PBS-C/M) was added. After gentle shaking for 30 min at 4°C, the cells were washed three times with the PBS-C/M solution and incubated with a quenching buffer (50 mM glycine in PBS-C/M) to remove excess biotin. Next, the cells were washed twice with PBS-C/M, lysed with RIPA buffer supplemented with 1× protease-inhibitor cocktail (Roche), and incubated overnight at 4°C with a slurry of neutravidin agarose beads (Thermo Scientific). The captured biotinylated proteins were eluted in 1× SDS-PAGE sample loading buffer supplemented with 50 mM DTT for 2 hr at room temperature and used for western blotting.

Measurement of heart rate in mice {#s4-15}
---------------------------------

Heart rates were measured using a previously described two-channel electrocardiogram (ECG) ([@bib65]), with certain modifications. Briefly, mice were anesthetized by intraperitoneally injecting them with an anesthetic and then placed on a 37°C heating plate., The anesthetic was 2.5% Avertin in PBS plus 2.5% DMSO (180 μL/20 g bodyweight) in most experiments, and 2 parts 10% ketamine, 1 part 2% xylazine, and 12 parts PBS (150 μL/20 g bodyweight) in some experiments. A small incision in the skin was made in the left paw and right lower abdomen for inserting a silver wire electrode subcutaneously. The ECG was recorded by using an Axopatch 200B amplifier and Axon DigiData1322A with Axon pClamp9 software; a 16 kΩ resistor was added in series with the amplifier to reduce the amplitude of the ECG and to avoid overshoot of the amplifier. The ECG was acquired at a sampling rate of 1 kHz and filtered at 5 kHz. The heart beats per minute were manually counted from 10 s recordings.

After recording a stable resting heart rate for at least 2 min, 0.04 mg isoproterenol (in PBS)/kg bodyweight was injected into mice intraperitoneally. Subsequently, the ECG was acquired for at least 8 min. The heart rates at 4 min after isoproterenol injection were counted as the isoproterenol-induced heart rates.

Intracellular cAMP assays {#s4-16}
-------------------------

Cells transfected with ACs were washed and incubated with or without 10 μM forskolin for 8 min. After washing once with room-temperature PBS, the cells were lysed by incubating them for 20 min with 0.1 M HCl at room temperature. The cell lysates were used for measuring cAMP levels (CYCLIC AMP EIA KIT; Biomedical Technologies Inc.) and protein concentrations (DC assays; BioRad).

Endocytosis and recycling assays {#s4-17}
--------------------------------

HeLa cells were transfected with various plasmids for 24 hr before experiments. Cell-surface proteins were biotinylated with the thiol-cleavable biotinylation reagent at 4°C as described above, and the internalization of biotinylated proteins was initiated by incubating cells at 37°C. Biotin was stripped from the biotinylated proteins remaining on the cell surface by using a MESNA buffer (50 mM MESNA, 100 mM NaCl, 50 mM Tris, 1 mM MgCl~2~, 0.1 mM CaCl~2~, pH 8.6) (1 hr, 4°C), and then the cells were either lysed in RIPA buffer for assessing the amount of internalized AC1 or again incubated for 10 min at 37°C to trigger the recycling of internalized biotin-labeled proteins to the cell surface; recycling was arrested by cooling the cells back down to 4°C. The recycled biotinylated proteins were stripped of biotin by using the MESNA buffer, and the cells were lysed to determine the biotinylated AC1 remaining in the cytosol. Biotinylated AC was quantitated using western blotting.

Quantitative real-time PCR {#s4-18}
--------------------------

Total RNA was extracted from the heart of wild-type and TRIP-Br1^−/−^ mice by using an RNA extraction kit (Takara Minibest universal RNA extraction kit), and cDNA was synthesized using Superscript II reverse transcriptase from Invitrogen. Quantitative PCR (qPCR) amplifications of various genes were performed using SYBR Green (Takara) and an ABI 7500 fast real-time PCR machine (Applied Biosystems); GAPDH was used as a normalization control. After initial denaturation (30 s, 95°C), amplification was performed using 40 cycles of 5 s at 95°C and 34 s at 60°C. All qPCR data represent means ± SEM. The sequences of the primers used for qPCR are listed below:

AC1: 5′-CCTCGCACTTACTGGTCACA-3′ and 5′-AACCCACGATGTCTGCAAAC-3′;

GAPDH: 5′-CTTGTCATCAACGGGAAGCC-3′ and 5′-CATGAGCCCTTCCACAATGC-3′.

Forskolin and isoproterenol treatment of mouse macrophages {#s4-19}
----------------------------------------------------------

Peritoneal macrohphages induced by Brewer thioglycollate medium were harvested from pathogen-free adult mice in cold PBS, as previously described ([@bib32]). After washed once with PBS and suspended in Roswell Park Memorial Institute (RPMI) medium with 10% FBS, macrophages harvested from one mouse were placed in a 6-well plate and incubated in a humidifiled CO~2~ (5%) incubator for 2 hr at 37°C. The macrophages adhered to the culture plate were washed once with PBS to remove nonadherent cells, followed by incubation in RPMI medium overnight at 37°C. Subsequently, the macrophages were washed one with PBS and incubated with DMSO (as vehicle), 10 µM forskolin (with 100 μM IBMX to block phosphodiesterases), or 10 μM isoproterenol in the absence or presence of the PKA inhibitor H89 (10 µM) in RPMI medium without serum for 6 hr. The microphages were then lysed with RIPA buffer with 1 x protease inhibitor cocktail and analyzed by western blotting.

Immunostaining and microscopy analysis of HeLa cells {#s4-20}
----------------------------------------------------

For confocal microscopy of Hela cells transfected with 3HA-AC1, 48 hr after transfection, cells were fixed with 4% paraformaldehyde (PFA) for 10 min and then washed once with PBS. The cells were then permeabilized and blocked with 3% bovine serum albumin (BSA) in a 'PBST' buffer (PBS plus 0.1% Triton X-100) for 30 min before incubated with rabbit anti-HA (1:100 dilution) and mouse anti-TRIP-Br1 (1:100 dilution) antibodies overnight at 4°C. Next, the cells were washed thrice (5 min each time) with the PBST buffer, followed by incubation with Alexa Fluor 488 conjugated goat anti-rabbit IgG and Alexa Fluor 647 conjugated goat anti-mouse IgG secondary antibodies (both 1:500 dilution) for 1 hr. Finally, the cells were washed thrice (5 min each time) with the PBST and subject to confocal microscopy.

For confocal microscopy of untransfected HeLa cells, cells seeded on coverslips were washed with PBS, incubated with/without (for control) anti-AC1 antibodies (1:50 dilution) in Opti-MEM containing Lipofectamine2000 (1:10 dilution) for 2 hr at 37°C, and then recovered in DMEM with 10% (v/v) FBS for 3 hr at 37°C ([@bib7]; [@bib27]). After fixation with 4% PFA in PBS, the cells were incubated at room temperature sequentially with biotin-conjugated anti-rabbit IgG secondary antibody (1:200 dilution) in 4% BSA in the PBST buffer for 1 hr, with NeutrAvidin (5 µg/mL, Pierce, cat\#31000) for 1 hr, and then with Atto 488 Biotin (20 µg/mL, Sigma-Aldrich, cat\#30574) for 1 hr; the cells were washed thrice (10 min each time) with PBS between each step. To detect TRIP-Br1, the cells were then incubated with anti-TRIP-Br1 antibody (1:200 dilution) in 4% BSA in the PBST for 1 hr, followed by incubation with Alexa Fluor 647 conjugated goat anti-mouse IgG antibody (1:200 dilution, Abcam, ab150115) and DAPI (1 µg/mL, Sigma-Aldrich) for 40 min. The sample was examined under a confocal microscope (Leica STED TCS SP5 II).

For stochastic optical reconstruction microscopy (STORM) analysis, HeLa cells seeded on No.1 18 mm round coverslips were washed twice with PBS, fixed with 4% PFA in PBS for 1 hr, permeabilized with the PBST for 10 min, and blocked with 4% BSA in PBS for 1 hr. The cells were then incubated with anti-AC1 and anti-TRIP-Br1 primary antibodies for 3 hr and with Alexa Fluor 647 conjugated goat anti-mouse IgG (1:200 dilution) and preadsorbed Alexa Fluor 750 conjugated goat anti-rabbit IgG (1:200 dilution, Abcam, ab175733) antibodies for 1.5 hr. The sample was kept in PBS until imaging. The sample was examined using STORM in an imaging buffer containing: 200 mM Tris-Cl (pH 9.0),10% (w/v) glucose, 5 U/mL glucose oxidase type VII (Sigma-Aldrich, cat\# G2133), 57 μg/mL catalase (Sigma-Aldrich, cat\#C3515), 2 mM cyclooctatetraene (Sigma-Aldrich, cat\#138924), 25 mM TCEP (Sigma-Aldrich, cat\#64654--7), 1 mM ascorbic acid (Sigma-Aldrich, cat\#A92902) and 1 mM methyl viologen (Sigma-Aldrich, cat\#856177). Images were analyzed using the image analysis software Fiji.

Statistics {#s4-21}
----------

Protein bands in western blots were quantified using ImageJ software. All data are expressed as means ± SEM. n denotes the number of independent biological replicates. Unless indicated otherwise, Student's two-tailed *t* test was used for statistical analysis, and p\<0.05 was considered statistically significant.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"The complex of TRIP-Br1 and *XIAP* ubiquitinates and degrades multiple adenylyl cyclase isoforms\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom, Volker Dötsch (Reviewer \#1), is a member of our Board of Reviewing Editors and the evaluation has been overseen by Jonathan Cooper as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

In this manuscript, the authors describe extensive biochemical studies revealing a *XIAP*/TRIP-Br1-dependent mechanism for regulating cellular protein levels of adenylyl cyclases. The authors show several lines of evidence supporting that TRIP-br1 functions as an adaptor of *XIAP* E3 ligase for AC ubiquitination and degradation. The authors propose that *XIAP*/TRIP-Br1-mediated degradation of ACs can serve as a negative-feedback mechanism for controlling homeostasis of cAMP signaling. Most experiments were done with AC1. Interaction of TRIP-br1 with ACs and *XIAP*/TRIP-Br1-dependent AC ubiquitination and AC protein levels were shown in several other AC isoforms. TRIP-Br1 knockout mice and *XIAP*-deltaRING mice exhibit increased AC protein levels, consistent with the authors\' model. The mutant mice also show AC-related physiological and behavioral phenotypes.

Essential revisions:

1\) The conclusion for [Figure 2A](#fig2){ref-type="fig"} and [Figure 2E](#fig2){ref-type="fig"} would be better supported by including quantification analysis.

2\) The ubiquitination assay in [Figure 4A](#fig4){ref-type="fig"} seems to mainly consist of one major band instead of the usual smear as seen for example in B. Any explanation? In this figure the expression level of TRIP-Br1 does not seem to increase with the overexpression of the flag tagged protein. Should the effect of overexpression and the resulting reduction of AC1 levels not be larger?

3\) K27 modifications are rather unusual. For degradation K48 would be the preferred one. The type of ubiquitination is linked to the E2. Is there any indication of which E2 is involved?

4\) Connected to the point above: A complete model would have to consider the binding and interaction of the E2 enzyme. Where would it interact with in the model in [Figure 9](#fig9){ref-type="fig"}?

Mouse work:

5\) In [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}, the authors show a battery of behavioral analyses and conclude that knocking out TRIP-Br1 causes anxiety-like behavior. However, the behavioral phenotypes could be more complex than simply being interpreted as anxiety-like disorder. For example, forced swimming test is conventionally used for depression or despair. Nesting test has not been generally adopted for anxiety disorder. The authors should provide more convincing justification in order to conclude an anxiety-like disorder or be more conservative in describing this apparent mood disorder phenotype.
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Author response

*Essential revisions:*

*1) The conclusion for [Figure 2A](#fig2){ref-type="fig"} and [Figure 2E](#fig2){ref-type="fig"} would be better supported by including quantification analysis.*

As suggested, the quantification of [Figures 2A and 2E](#fig2){ref-type="fig"} is now included in the revised [Figure 2](#fig2){ref-type="fig"}.

*2) The ubiquitination assay in [Figure 4A](#fig4){ref-type="fig"} seems to mainly consist of one major band instead of the usual smear as seen for example in B. Any explanation? In this figure the expression level of TRIP-Br1 does not seem to increase with the overexpression of the flag tagged protein. Should the effect of overexpression and the resulting reduction of AC1 levels not be larger?*

Depending on the conditions of SDS-PAGE, such as gel concentrations and electrophoresis/separation time, the pattern of ubiquitinated AC1 may appear different. The experiment in original [Figure 3C](#fig3){ref-type="fig"} used 10% gel (vs. 8% gel in other experiments; see the molecular markers) and relatively short running time and therefore ubiquitinated AC1 appeared more condensed, but still smeared, especially in the last two lanes. Nevertheless, most of the ubiquitinated AC1 are between 170 and 130 kD in both 8% and 10% gel.

It has been reported by various labs that FLAG tag masks the antigen of protein specific antibodies in western blotting for unclear reasons. In our case, FLAG-tagged TRIP-Br1 was barely detected by our anti-TRIP-Br1 antibody, unless the protein sample was boiled and added with 200 mM DTT ([Author response image 1](#fig10){ref-type="fig"}). However, boiling would make AC1 aggregate. Therefore, the protein sample in [Figure 4A](#fig4){ref-type="fig"} was not boiled, and FLAG-tagged TRIP-Br1 was hardly detected by anti-TRIP-Br1 antibody. The original purpose to display the signals detected by anti-TRIP-Br1 antibody in [Figure 4A](#fig4){ref-type="fig"} was mainly to show that endogenous TRIP-Br1 was not affected by overexpression of *XIAP*. This panel was removed in the revised figure to avoid confusion.

Overexpression of transient FLAG-tagged TRIP-Br1 seemed to result in average 50% reduction in AC1 (see the large collective sample size in [Figure 5A](#fig5){ref-type="fig"}, including wild-type and mutant AC1). 30 to 70% reduction ([Figure 4A and 4C](#fig4){ref-type="fig"}) could be fluctuations around 50% because of the relative sample sizes.

In addition, we added a new panel ([Figure 4E](#fig4){ref-type="fig"}) to further support the data in [Figure 4A](#fig4){ref-type="fig"} and other panels in [Figure 4](#fig4){ref-type="fig"}. [Figure 4E](#fig4){ref-type="fig"} shows that deleting the RING domain of *XIAP* abolished the effect of TRIP-Br1 knockout in the mouse brain, further fortifying the notion that *XIAP* and TRIP-Br1 act in concert.10.7554/eLife.28021.021Author response image 1.TRIP-Br1-FLAG was detected by TRIP-Br1 antibody.HeLa cells were seeded in a 60-mm dish the day before the transfection. 5 ug TRIP-Br1-FLAG or control vector were transfected into the HeLa cells. After 48 h culture, cells were lysed by RIPA buffer and the cell lysate was boiled at 95°C for 10 min and added with 200 mM DTT before subject to western blotting by anti-FLAG and anti-TRIP-Br1 antibodies separately. 12% gel was used for better separation of endogenous (arrowhead) and FLAG-tagged TRIP-Br1.**DOI:** [http://dx.doi.org/10.7554/eLife.28021.021](10.7554/eLife.28021.021)

*3) K27 modifications are rather unusual. For degradation K48 would be the preferred one. The type of ubiquitination is linked to the E2. Is there any indication of which E2 is involved?*

We thank the reviewers to bring up this point. Although K27 linkages are indeed less abundant than K48 linkages, recent studies seem to suggest that K27 linkages are much more abundant than previously expected (9% K27 vs. 29% K48 linkages in the yeast) \[1\]. Numerous studies indicate that K27 linkage is involved in proteolytic functions \[1-4\].

UbcH5A, B, and C, which share 92% identity, have been functionally demonstrated to serve as the E2s of XIAP \[5-9\]. In our in-vitro ubiquitination assays, we used UbcH5B as the E2 of *XIAP* ([Figure 5C](#fig5){ref-type="fig"}). Importantly, UbcH5A or UbcH5B reportedly catalyses formation of K27 linages \[2, 10\]. Limited studies suggest that *XIAP* may physically interact with several other E2 enzymes \[11, 12\] but whether they serve as the E2s of *XIAP* is not known or rejected \[9\].

We added several sentences and relevant references in the revised paper to address this issue.

*4) Connected to the point above: A complete model would have to consider the binding and interaction of the E2 enzyme. Where would it interact with in the model in [Figure 9](#fig9){ref-type="fig"}?*

Previous studies show UbcH5B binds to the Ring domain of XIAP \[7, 6\]. We added UbcH5B in the model in [Figure 9](#fig9){ref-type="fig"}.

*Mouse work:*

*5) In [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}, the authors show a battery of behavioral analyses and conclude that knocking out TRIP-Br1 causes anxiety-like behavior. However, the behavioral phenotypes could be more complex than simply being interpreted as anxiety-like disorder. For example, forced swimming test is conventionally used for depression or despair. Nesting test has not been generally adopted for anxiety disorder. The authors should provide more convincing justification in order to conclude an anxiety-like disorder or be more conservative in describing this apparent mood disorder phenotype.*

As suggested, we used a more conservative description: "anxiety-like behaviour" is replaced by "mood disorder, especially despair-like behaviour".
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